Physician profile
David Calderone
NPI 1144290115
$2,046.93
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $13.45 · 2021: $1,010.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $900.00 | 2021 | |
| Smith+Nephew, INC. | $248.73 | 2019 | |
| Cardiovascular Systems INC. | $172.19 | 2019-2021 | |
| Celgene Corporation | $132.21 | 2019 | |
| Avinger INC. | $124.23 | 2019 | |
| Abbott Laboratories | $114.65 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $96.20 | 2019 | |
| Arteriocyte Medical Systems, INC. | $94.63 | 2019 | |
| Osiris Therapeutics INC. | $35.52 | 2019 | |
| Horizon Therapeutics Plc | $24.49 | 2019 | |
| Acera Surgical, INC. | $18.11 | 2021 | |
| Osteomed LLC | $16.63 | 2019 | |
| Wright Medical Technology, INC. | $14.96 | 2019 | |
| Stryker Corporation | $14.13 | 2019 | |
| Melinta Therapeutics, LLC | $13.46 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $13.45 | 2020 | |
| Bioventus LLC | $13.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Calderone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.